About ALung Technologies
ALung Technologies develops intra and extracorporeal gas exchange devices for the treatment of acute and chronic respiratory disorders. The company's current lead product under development is the Hemolung. This device is an extracorporeal gas exchange device that circulates blood via a small catheter the same size as a dialysis catheter. By directly delivering oxygen (O2) to the blood and removing carbon dioxide (CO2) from the blood, the Hemolung is expected to deliver a clinically and economically ventilation solution than mechanical ventilation. This device is capable of supporting patients with acute breathing problems for 7 days, providing their lungs with a bridge to recovery. The company was founded in 1997 and is based in Pittsburgh, Pennsylvania. In May 2022, ALung Technologies was acquired by LivaNova.
Missing: ALung Technologies's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: ALung Technologies's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Research containing ALung Technologies
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned ALung Technologies in 1 CB Insights research brief, most recently on Mar 12, 2020.
Expert Collections containing ALung Technologies
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
ALung Technologies is included in 2 Expert Collections, including Medical Devices.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
ALung Technologies Patents
ALung Technologies has filed 3 patents.
Fluid dynamics, Fiber bundles, Differential geometry, Actuators, Algebraic topology
Fluid dynamics, Fiber bundles, Differential geometry, Actuators, Algebraic topology
Latest ALung Technologies News
Nov 18, 2022
Extracorporeal Membrane Oxygenation Machine Market to Display Impressive Growth of 5% with Rising Demand [311 Pages Report] The extracorporeal membrane oxygenation systems market is progressing steadily with a CAGR of 5% from 2022-2032, as per the extracorporeal membrane oxygenation systems market analysis by Future Market Insights (FMI). Recent developments in extracorporeal membrane oxygenation systems market innovations such as miniaturization of ECMO components like hollow pumps, which are used in various surgeries, aids in the transportation of critically ill patients, thereby increasing the ECOM systems market size. As per the ECOM systems market study, the rising use of ECMO has sparked technological advancements in extracorporeal membrane oxygenation machines of which oxygenators and heparin-coated cannulas are two major emerging trends in the ECOM systems market. The study finds that extracorporeal membrane oxygenation devices are used in life-threatening situations when other forms of supportive care have failed. Furthermore, the use of ECMO in various healthcare settings has increased significantly owing to its wide range of applications. The adoption of ECMO procedures is being promoted by several government organizations. One of them is GOLD (Global Initiative for Chronic Obstructive Lung Disease), a campaign that aims to raise awareness about COPD and its treatment, which includes the use of ECMO oxygen machine thereby positively influencing the ECMO systems adoption trends. The sudden spike in COVID-19 cases, combined with an increase in the number of critically ill patients requiring additional life support, has pushed up demand for ECMO machines. For patients with severe acute respiratory distress syndrome, extracorporeal membrane oxygenation therapy has been the preferred treatment option. An increasing number of supportive government policies and the rapid FDA approval of extracorporeal membrane oxygenation equipment for emergency use have significantly increased the ECOM systems market opportunities. Moreover, several companies are scaling up ECOM systems’ market share by expanding their manufacturing capabilities to meet the rising demand for assistive technologies. On account of the factors mentioned above, the ECOM systems market is predicted to muster a revenue of about US$ 673 Mn by 2026. Key Takeaways: By application, high demand for early diagnosis and diagnostic imaging, and technological advancements in the extracorporeal membrane oxygenation machine market are expected to propel the respiratory segment to the top. The arterio-venous segment is likely to hold the majority of the market based on modality owing to the benefits associated with this technology segment, such as effective dynamic range, thereby boosting the ECMO systems market growth. Based on patient type, the adult segment is projected to lead the market as the global burden of cardiac and respiratory diseases in adults is rising due to increased consumption of alcohol, tobacco, smoking, and a sedentary lifestyle. Based on components, the controller’s segment is expected to dominate the market, and the same can be credited to the systems’ higher adoption among end-users as a result of their lower cost when compared to others. The portable ECMO machine segment is expected to dominate the market by product type. They are lightweight and portable, allowing them to be transported to any desired location, influencing the ECMO systems market future trends. Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-14300 “North American market is anticipated to be at the forefront of the ECMO systems market because of the presence of key players and the rising number of product launches, government support for high-quality healthcare which is also considered to be a few crucial ECMO systems market trends and the rising prevalence of diseases in the United States and Canada, such as chronic obstructive pulmonary disease resulting in increased hospital admission favoured by reimbursement policies, is expected to boost the sales of ECMO systems in this region.” asserts an FMI analyst. Competitive Landscape: Companies like Abbott Laboratories, Medtronic, Alung Technologies, and Terumo Corporation dominate the global market. Major global players produce the majority of ECMO support systems. Market leaders have established their position by investing more in research and having a better distribution system. To stay competitive in the market, extracorporeal membrane oxygenation machines manufacturers are actively involved in product launches and technological innovation. ALung Technologies, Inc. has begun commercialization of its ground-breaking next-generation artificial lung. The device is based on University of Pittsburgh intellectual property licensed to ALung Technologies, Inc. Medtronic has released its artificial lung therapy for the treatment of COVID-19. An artificial pump that pumps blood from a person’s body to an oxygenator is called ECMO, and it also has an FDA-approved device for ECMO procedures lasting up to 6 hours. For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-14300 Key Segments By Product:
ALung Technologies Frequently Asked Questions (FAQ)
When was ALung Technologies founded?
ALung Technologies was founded in 1997.
Where is ALung Technologies's headquarters?
ALung Technologies's headquarters is located at 2500 Jane Street, Pittsburgh.
What is ALung Technologies's latest funding round?
ALung Technologies's latest funding round is Acquired.
How much did ALung Technologies raise?
ALung Technologies raised a total of $145.12M.
Who are the investors of ALung Technologies?
Investors of ALung Technologies include LivaNova, Paycheck Protection Program, Birchmere Ventures, UPMC Enterprises, Allos Ventures and 18 more.
Who are ALung Technologies's competitors?
Competitors of ALung Technologies include SetPoint Medical, PulmonX, Nyxoah, Light Sciences Oncology, Game Ready, SteadyMed Therapeutics, Valtech Cardio, Celleration, Activaero, Hotspur Technologies and 14 more.
Compare ALung Technologies to Competitors
Portaero, in stealth mode, is a medical devices firm, developing a device for the treatment of COPD (Chronic obstructive pulmonary disease).
Pathfinder Therapeutics (PTI) is the developer of Explorer, an image-guided "GPS" device that enables physicians to accurately and efficiently guide the delivery of cancer therapeutics (usually resection and/or ablation) in soft-tissue organs. Explorer is cleared by the FDA in the category of Intraoperative Soft Tissue Tracking. Scout, the company's advanced 3D planning software, provides highly detailed visual and volumetric information for preoperative assessment, thus enabling clinicians to visualize the site of disease, plan the resection and/or ablation and monitor the resultant effects.
Mobius Therapeutics is a commercial stage venture focused on ophthalmic surgery solutions. Its first product, Mitosol, is a system for delivering antifibrotic agents in glaucoma, refractive, and corneal surgery. The glaucoma indication is in active commercialization; the pterygium and refractive indications are awaiting approval by the Food and Drug Administration.
Stealth mode medical device company developing devices for drug delivery. Monterey Devices submitted a patent on device for buffering anesthetics.
Relievant provides the underserved population with a low-risk therapy that can eliminate back pain while preserving other therapeutic options. The Company's Intracept System is a minimally invasive procedure that uses radiofrequency energy delivered through a small access tube into the vertebral body to ablate the Basivertebral nerve. The nerve, thought to significantly contribute to chronic low back pain, can no longer generate pain signals following ablation. The company was founded in 2004 and is based in Minneapolis, Minnesota.
SetPoint Medical develops a bioelectronic medicine platform using a small implanted device that activates the body's natural inflammatory reflex and produces a systemic anti-inflammatory effect. It aims to treat patients with chronic autoimmune diseases and provides a treatment alternative for rheumatoid arthritis, inflammatory bowel disease, and other chronic autoimmune conditions. The company was founded in 2006 and is based in Santa Clarita, California.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.